Segui
Lavinia Spain
Lavinia Spain
Peter MacCallum Cancer Centre & Eastern Health
Email verificata su monash.edu
Titolo
Citata da
Citata da
Anno
Management of toxicities of immune checkpoint inhibitors
L Spain, S Diem, J Larkin
Cancer treatment reviews 44, 51-60, 2016
8832016
Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal
S Turajlic, H Xu, K Litchfield, A Rowan, T Chambers, JI Lopez, D Nicol, ...
Cell 173 (3), 581-594. e12, 2018
7002018
Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal
S Turajlic, H Xu, K Litchfield, A Rowan, S Horswell, T Chambers, ...
Cell 173 (3), 595-610. e11, 2018
5402018
Fc effector function contributes to the activity of human anti-CTLA-4 antibodies
FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ...
Cancer cell 33 (4), 649-663. e4, 2018
5312018
Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal
TJ Mitchell, S Turajlic, A Rowan, D Nicol, JHR Farmery, T O’Brien, ...
Cell 173 (3), 611-623. e17, 2018
4612018
Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors
FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ...
Immunity 46 (4), 577-586, 2017
4092017
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
S Diem, B Kasenda, L Spain, J Martin-Liberal, R Marconcini, M Gore, ...
British journal of cancer 114 (3), 256-261, 2016
3092016
Pervasive chromosomal instability and karyotype order in tumour evolution
TBK Watkins, EL Lim, M Petkovic, S Elizalde, NJ Birkbak, GA Wilson, ...
Nature 587 (7832), 126-132, 2020
2602020
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
J Haanen, M Obeid, L Spain, F Carbonnel, Y Wang, C Robert, AR Lyon, ...
Annals of Oncology 33 (12), 1217-1238, 2022
2472022
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
L Spain, G Walls, M Julve, K O’Meara, T Schmid, E Kalaitzaki, S Turajlic, ...
Annals of Oncology 28 (2), 377-385, 2017
2442017
Thyroid abnormalities following the use of cytotoxic T‐lymphocyte antigen‐4 and programmed death receptor protein‐1 inhibitors in the treatment of melanoma
DL Morganstein, Z Lai, L Spain, S Diem, D Levine, C Mace, M Gore, ...
Clinical endocrinology 86 (4), 614-620, 2017
2022017
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
L Au, E Hatipoglu, MR de Massy, K Litchfield, G Beattie, A Rowan, ...
Cancer cell 39 (11), 1497-1518. e11, 2021
1482021
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
L Spain, R Higgins, K Gopalakrishnan, S Turajlic, M Gore, J Larkin
Annals of Oncology 27 (6), 1135-1137, 2016
1402016
Illness perception and health-related quality of life in multiple sclerosis
L Spain, N Tubridy, T Kilpatrick, S Adams, A Holmes
Acta Neurologica Scandinavica 116 (5), 293-299, 2008
1192008
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
M Tio, R Rai, OM Ezeoke, JL McQuade, L Zimmer, C Khoo, JJ Park, ...
European Journal of Cancer 104, 137-144, 2018
1142018
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP …
JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ...
The Lancet Oncology 23 (11), 1389-1397, 2022
802022
Representative sequencing: unbiased sampling of solid tumor tissue
K Litchfield, S Stanislaw, L Spain, LL Gallegos, A Rowan, D Schnidrig, ...
Cell reports 31 (5), 2020
592020
Selection of metastasis competent subclones in the tumour interior
Y Zhao, X Fu, JI Lopez, A Rowan, L Au, A Fendler, S Hazell, H Xu, ...
Nature ecology & evolution 5 (7), 1033-1045, 2021
542021
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
R Kramer, A Zaremba, A Moreira, S Ugurel, DB Johnson, JC Hassel, ...
European Journal of Cancer 147, 170-181, 2021
482021
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
N Powell, H Ibraheim, T Raine, RA Speight, S Papa, O Brain, M Green, ...
The Lancet Gastroenterology & Hepatology 5 (7), 679-697, 2020
432020
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20